Clinical Trials Browser

Sarcoma, Ewing, Osteosarcoma

NCT02867592 2026-04-13

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3 Active not recruiting

298 enrolled 14 charts 3 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03914300 2026-04-13

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Phase 2 Active not recruiting

11 enrolled 11 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT04079712 2026-04-13

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Phase 2 Active not recruiting

17 enrolled 12 charts

EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04211337 2026-03-19

LIBRETTO-531

Phase 3 Active not recruiting

291 enrolled 16 charts 3 FDA

Carcinoma, Medullary

NCT04338269 2026-03-19

CONTACT-03

Phase 3 Terminated

522 enrolled 22 charts

Genitourinary

Carcinoma, Renal Cell

Clinical Trials

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

LIBRETTO-531

CONTACT-03

CaboPoint

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

CheckMate040

CONTACT-01

CONTACT-02

COSMIC-312

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

COSMIC-313

EXAMINER

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

CABATEN

CheckMate 9ER

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

ACTION

Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

Cabozantinib and Nivolumab for Carcinoid Tumors

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

PemCab

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

NF105-CABO

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

CANTATA

Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

Cabozantinib for Advanced Urothelial Cancer

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children